SYGNIS signs distribution agreement with Mayflower Bioscience for the US market
- Mayflower Bioscience is a leading life science distributor focused on life science research products
- Important step to build SYGNIS’ presence in the USA
Madrid, Spain and Heidelberg, Germany, December 2nd, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a distribution agreement with Mayflower Bioscience LLC (St. Louis, USA) for the commercialization of SYGNIS’ proprietary product portfolio in the USA.
Under the terms of the agreement, SYGNIS has granted Mayflower Bioscience the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in the USA. These product lines cover the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
Mayflower Bioscience is a distributor of unique life science research products, providing their customers with the latest innovations for biological research, drug discovery and bioproduction, with an emphasis on solutions for cell biology, molecular biology and drug discovery.
“The distribution agreement with Mayflower represents the next logical and consistent step in SYGNIS’ strategy. After having successfully built an extensive distibution network covering the most important life science markets in Europe and Asia, we are now entering the USA, the biggest and fastest growing life science market worldwide,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Mayflower is a specialist provider particularly for high level research centers focused on Next Generation Sequencing (NGS). The NGS market in the USA represents more than 50% of the global market. Mayflower provides a broad US customer data base and deep knowledge of the customers needs, and is ideally suited to market and commercialize our existing and future product portfolio.”
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered via SYGNIS’ own online shop under http://www.sygnis.com/shop.
TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScriptTM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30